{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:06:36Z","timestamp":1770516396792,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1245\/s10434-020-08322-y","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T14:02:41Z","timestamp":1586786561000},"page":"1780-1787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms"],"prefix":"10.1245","volume":"27","author":[{"name":"Chicago Consensus Working Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"8322_CR1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08318-8","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08318-8.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08317-9","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08317-9.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08325-9","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08325-9.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08316-w","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08316-w.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08315-x","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08315-x.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08320-0","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08320-0.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08324-w","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08324-w.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08321-z","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08321-z.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08319-7","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08319-7.","journal-title":"Ann Surg Oncol."},{"key":"8322_CR10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08323-x","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08323-x.","journal-title":"Ann Surg Oncol."},{"issue":"9951","key":"8322_CR11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376\u20131388.","journal-title":"Lancet."},{"issue":"24","key":"8322_CR12","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter 3rd","year":"2007","unstructured":"Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621\u20133627.","journal-title":"J Clin Oncol."},{"issue":"3","key":"8322_CR13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s12032-011-0019-5","volume":"29","author":"V Asher","year":"2012","unstructured":"Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 2012;29(3):2005\u20132009.","journal-title":"Med Oncol."},{"issue":"5","key":"8322_CR14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4149\/neo_2013_071","volume":"60","author":"H Huang","year":"2013","unstructured":"Huang H, Li YJ, Lan CY, et al. Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 2013;60(5):546\u2013552.","journal-title":"Neoplasma."},{"issue":"4","key":"8322_CR15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382\u2013390.","journal-title":"JAMA."},{"issue":"4","key":"8322_CR16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482\u2013490.","journal-title":"JAMA Oncol."},{"issue":"44","key":"8322_CR17","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032\u201318037.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"8322_CR18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u20131284.","journal-title":"Lancet Oncol."},{"issue":"26","key":"8322_CR19","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u20132505.","journal-title":"N Engl J Med."},{"issue":"6","key":"8322_CR20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u20131244.","journal-title":"Cancer."},{"issue":"12","key":"8322_CR21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680\u20131687.","journal-title":"Lancet Oncol."},{"issue":"4","key":"8322_CR22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2006.07.7800","volume":"25","author":"AE Axtell","year":"2007","unstructured":"Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384\u2013389.","journal-title":"J Clin Oncol."},{"issue":"8","key":"8322_CR23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","volume":"13","author":"A Fagotti","year":"2006","unstructured":"Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156\u20131161.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"8322_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2018.10.017","volume":"151","author":"JM Hansen","year":"2018","unstructured":"Hansen JM, Sood AK, Coleman RL, et al. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018;151(3):428\u2013432.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"8322_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/GMIT.GMIT_1_17","volume":"7","author":"AS El-Agwany","year":"2018","unstructured":"El-Agwany AS. Laparoscopy and computed tomography imaging in advanced ovarian tumors: a roadmap for prediction of optimal cytoreductive surgery. Gynecol Minim Invasive Ther. 2018;7(2):66\u201369.","journal-title":"Gynecol Minim Invasive Ther."},{"issue":"15_suppl","key":"8322_CR26","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"RL Coleman","year":"2018","unstructured":"Coleman RL, Enserro D, Spirtos N, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology\/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36(15_suppl):5501\u20135501.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"8322_CR27","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clinical Oncol. 2017;35(15_suppl):5501\u20135501.","journal-title":"J Clinical Oncol."},{"issue":"9","key":"8322_CR28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933\u20131939.","journal-title":"Cancer."},{"issue":"26","key":"8322_CR29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u20132483.","journal-title":"N Engl J Med."},{"issue":"26","key":"8322_CR30","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u20132496.","journal-title":"N Engl J Med."},{"issue":"10","key":"8322_CR31","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020\u20131026.","journal-title":"Lancet Oncol."},{"issue":"1","key":"8322_CR32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med."},{"issue":"1","key":"8322_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2016.06.011","volume":"142","author":"JL Walker","year":"2016","unstructured":"Walker JL. Intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol. 2016;142(1):1\u20132.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"8322_CR34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","volume":"25","author":"LB Wenzel","year":"2007","unstructured":"Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437\u2013443.","journal-title":"J Clin Oncol."},{"issue":"8","key":"8322_CR35","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738\u2013748.","journal-title":"N Engl J Med."},{"issue":"4","key":"8322_CR36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396\u2013405.","journal-title":"Lancet Oncol."},{"issue":"4","key":"8322_CR37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588\u2013591.","journal-title":"Br J Cancer."},{"issue":"15","key":"8322_CR38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"JA Ledermann","year":"2012","unstructured":"Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u20131392.","journal-title":"N Engl J Med."},{"issue":"8","key":"8322_CR39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928\u2013936.","journal-title":"Lancet Oncol."},{"issue":"1","key":"8322_CR40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol."},{"issue":"22","key":"8322_CR41","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u20132164.","journal-title":"N Engl J Med."},{"issue":"17","key":"8322_CR42","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039\u20132045.","journal-title":"J Clin Oncol."},{"issue":"10106","key":"8322_CR43","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u20131961.","journal-title":"Lancet."},{"issue":"11","key":"8322_CR44","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"A Buda","year":"2004","unstructured":"Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90(11):2112\u20132117.","journal-title":"Br J Cancer."},{"issue":"19","key":"8322_CR45","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176\u20133182.","journal-title":"J Clin Oncol."},{"issue":"2","key":"8322_CR46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","volume":"23","author":"A Lortholary","year":"2012","unstructured":"Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346\u2013352.","journal-title":"Ann Oncol."},{"issue":"13","key":"8322_CR47","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20131308.","journal-title":"J Clin Oncol."},{"issue":"2","key":"8322_CR48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdx754","volume":"29","author":"DM Provencher","year":"2018","unstructured":"Provencher DM, Gallagher CJ, Parulekar WR, et al. OV21\/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431\u2013438.","journal-title":"Ann Oncol."},{"issue":"3","key":"8322_CR49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u2013240.","journal-title":"N Engl J Med."},{"issue":"5","key":"8322_CR50","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20131575.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"8322_CR51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","volume":"41","author":"YR Huo","year":"2015","unstructured":"Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578\u20131589.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"8322_CR52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1634\/theoncologist.2015-0500","volume":"21","author":"M Petrillo","year":"2016","unstructured":"Petrillo M, Anchora LP, Scambia G, Fagotti A. Cytoreductive surgery plus platinum-based hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: a promising integrated approach to improve locoregional control. Oncologist. 2016;21(5):532\u2013534.","journal-title":"Oncologist."},{"issue":"9 Suppl 3","key":"8322_CR53","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/IGC.0000000000000296","volume":"24","author":"JA Ledermann","year":"2014","unstructured":"Ledermann JA, Luvero D, Shafer A, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14\u201319.","journal-title":"Int J Gynecol Cancer."},{"issue":"6","key":"8322_CR54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/bjs.10716","volume":"105","author":"JB Delhorme","year":"2018","unstructured":"Delhorme JB, Severac F, Averous G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg. 2018;105(6):668\u2013676.","journal-title":"Br J Surg."},{"issue":"6","key":"8322_CR55","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1245\/s10434-018-6464-z","volume":"25","author":"F Mercier","year":"2018","unstructured":"Mercier F, Bakrin N, Bartlett DL, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol. 2018;25(6):1668\u20131675.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08322-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T23:04:25Z","timestamp":1618268665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08322-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["8322"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08322-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bhavana Pothuri serves on the advisory boards of Eisai, AstraZeneca, and Clovis Oncology and has received travel support from Tesaro to present at scientific meetings, all outside the submitted work. James C. Cusack reports grants from Lumicell Inc. outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and non-financial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, BMS, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, BMS, Deciphera, GSK, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare, and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The remaining authors disclosed no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}